StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) stock

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.61+0.28 (+1.02%)

Close on Nov 18, 2026Market cap $3.47BP/E 125.5Yield –

Arcutis Biotherapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Arcutis Biotherapeutics's revenue for the twelve months ending Jun 30, 2026 was $463.98M, up 76.1% year over year. For fiscal 2025 it was $376.07M, up 91.3% from the year before. The highest annual figure on record is $376.07M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$376.07M+91.3%
FY2024Dec 31, 2024$196.54M+229.7%
FY2023Dec 31, 2023$59.61M+1517.1%
FY2022Dec 31, 2022$3.69M–
FY2021Dec 31, 2021$0–
FY2020Dec 31, 2020$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$129.86M+59.3%
Q1 FY2026Mar 31, 2026$105.40M+60.1%
Q4 FY2025Dec 31, 2025$129.50M+81.5%
Q3 FY2025Sep 30, 2025$99.22M+121.7%
Q2 FY2025Jun 30, 2025$81.50M+164.1%
Q1 FY2025Mar 31, 2025$65.85M+32.8%
Q4 FY2024Dec 31, 2024$71.36M+427.6%
Q3 FY2024Sep 30, 2024$44.76M+17.4%
Q2 FY2024Jun 30, 2024$30.86M+494.6%
Q1 FY2024Mar 31, 2024$49.57M+1682.4%
Q4 FY2023Dec 31, 2023$13.53M+356.8%
Q3 FY2023Sep 30, 2023$38.11M+5156.4%
Q2 FY2023Jun 30, 2023$5.19M–
Q1 FY2023Mar 31, 2023$2.78M–
Q4 FY2022Dec 31, 2022$2.96M–
Q3 FY2022Sep 30, 2022$725.00K–
Q2 FY2022Jun 30, 2022$0–
Q1 FY2022Mar 31, 2022$0–
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–

More Arcutis Biotherapeutics figures

See a number that looks wrong?